Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05729568 · ClinicalTrials.gov registry record · Phase 2

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

A Phase 2 study of HIV Infection, sponsored by Gilead Sciences.

Active
Registry status
Phase 2
Development phase
83
Enrollment target
20
Study locations

NCT05729568 is a Phase 2 study of HIV Infection that is active but no longer recruiting, run by Gilead Sciences. The registered enrollment target is 83 participants, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05729568, a Phase 2 study of HIV Infection, is active but no longer recruiting, sponsored by Gilead Sciences.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
83 participants
Enrollment target
20
Study locations

Study Summary

The goal of this study is to test the effectiveness, safety, and tolerability of the combination of broadly neutralizing antibodies (bNAbs) (teropavimab (TAB; GS-5423) and zinlirvimab (ZAB; GS-2872)) with lenacapavir (LEN) in virologically suppressed adults with HIV-1 infection. The purpose of this study is to evaluate the efficacy of switching to a regimen of LEN, TAB and ZAB, versus continuing on baseline oral antiretroviral therapy (ART) as determined by the proportion of participants with human immunodeficiency virus-1 (HIV-1) ribonucleic acid (RNA) ≥ 50 copies/mL at Week 26.

Conditions Studied

HIV Infection

Interventions

  • DRUG Lenacapavir Injection
  • DRUG Lenacapavir Tablet
  • DRUG Teropavimab
  • DRUG Zinlirvimab
  • DRUG Antiretroviral Therapy

Study Locations (20)

Florida

  • Midland Florida Clinical Research Center, LLC - DeLand
  • Can Community Health Care - Fort Lauderdale
  • Midway Immunology and Research Center - Ft. Pierce
  • Orlando Immunology Center - Orlando
  • Triple O Research Institute, P.A. - West Palm Beach

California

  • Ruane Clinical Research Group, Inc. - Los Angeles
  • Mills Clinical Research - Los Angeles
  • UC San Diego (UCSD) AntiViral Research Center (AVRC) - San Diego
  • Optimus Medical Group - San Francisco

North Carolina

  • NC TraCS Institute - CTRC; University of North Carolina at Chapel Hill - Chapel Hill
  • Duke University Health Center - Durham
  • Regional Center for Infectious Disease Research - Greensboro

Georgia

  • Emory University Hospital Midtown Infectious Disease Clinic - Atlanta
  • Infectious Disease Specialists of Atlanta - Decatur

Colorado

  • University of Colorado Clinical and Translational Research Center - Aurora

Connecticut

  • Yale University; School of Medicine; AIDS Program - New Haven

District of Columbia

  • Georgetown University Medical Center - Washington D.C.

Missouri

  • Southhampton Healthcare, Inc - St Louis

Trial Details

FieldValue
Enrollment Target 83 participants
Start Date 2023-05-15
Est. Completion 2029-12
Phase Phase 2

Sponsor

Gilead Sciences

504 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05729568

The ClinicalTrials.gov registry entry for NCT05729568 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (66% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infection appearing as the primary indexed condition, and to 5 interventions - of which Lenacapavir Injection is the first listed.

NCT05729568 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, North Carolina.

Frequently Asked Questions

What is clinical trial NCT05729568 about?

NCT05729568 is a clinical study titled "A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection". The goal of this study is to test the effectiveness, safety, and tolerability of the combination of broadly neutralizing antibodies (bNAbs) (teropavimab (TAB; GS-5423) and zinlirvimab (ZAB; GS-2872)) with lenacapavir (LEN) in virologically suppressed adults with HIV-1 infection. The purpose of this...

What is the current status of trial NCT05729568?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2023-05-15. Estimated completion is 2029-12.

What conditions does trial NCT05729568 study?

This clinical trial studies the following conditions: HIV Infection.

What interventions are being tested in trial NCT05729568?

The interventions under investigation include: Lenacapavir Injection (DRUG), Lenacapavir Tablet (DRUG), Teropavimab (DRUG), Zinlirvimab (DRUG), Antiretroviral Therapy (DRUG).

Who is sponsoring clinical trial NCT05729568?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05729568 being conducted?

This trial has 20 study locations across California, Colorado, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infection

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.